PWE-169 Treatment of oesophageal cell lines with docosahexaenoic fatty acid (DHA) and oxaliplatin: effects on proliferation, expression of vascular endothelial growth factor and IL-6

Abstract

<h3>Introduction</h3> Oesophageal cancer is a very aggressive disease, and despite advances in cancer treatment, the prognosis is still poor. Growth factors such as vascular endothelial growth factor (VEGF) and pro-inflammatory markers have a major role in cancer progression, survival and metastasis. We examined anti-proliferative effects of DHA and oxaliplatin on two oesophageal cancer cell lines, in addition to assessing effects on VEGF and the inflammatory cytokine IL-6. <h3>Method</h3> Two Oesophageal cell lines (OE33 and OE19) were treated with either DHA or Oxaliplatin (0–50 µM) and incubated for up to 144 h. Cell counts were measured using a Z2 particle size analyser and expression of VEGF and IL-6 measured in cell culture supernatant using MSD ELISA kits. Three way ANOVA was used to analyse the data using StataIC 13 software. <h3>Results</h3> DHA reduced proliferation of OE33 and OE19 cell lines by 59% (p &lt; 0.001) and 26% (p = 0.019) respectively. Oxaliplatin reduced proliferation by 77% (p &lt; 0.001) and 76% (p &lt; 0.001) respectively, growth curve demonstrated in the Figure 1. Down regulation of VEGF expression in OE33 cells after 144 h DHA treatment (50 µM) was highly significant (p &lt; 0.0001, 95% CI -664.04 to -544.27) as was Oxaliplatin treatment (50 µM) (p &lt; 0.0001, 95% CI -803.97 to -581.70). OE19 cells exhibited sensitivity to both drugs at lower concentrations at this same time point; DHA (30 µM) (p = 0.005, 95% CI -63.88 to -19.57) and Oxaliplatin (20 µM) (p = 0.026 95% CI -73.1 to -6.54). The two drugs had no statistically significant inhibition of IL-6 expression in both cell lines despite inhibition of cell growth. <h3>Conclusion</h3> The data provide evidence that the DHA and Oxaliplatin have statistically significant down regulation effect of VEGF in the two oesophageal cell lines but didn’t alter expression of pro-inflammatory markers such as IL-6. <h3>Disclosure of interest</h3> None Declared.